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SummAry – treatment modalities affecting quality of life and survival in elderly brain glioblas-
toma patients are not well defined. A single-institution data were analyzed during a 3-year period to 
disclose prognostic difference in management related to age. Karnofsky Performance Scale (KPS), 
overall survival (OS), and adjuvant therapy were evaluated. The case group comprised of elderly pa-
tients (>75 years), while the control group included those of younger age (<65 years). The investigated 
variables were correlated between the groups. twenty elderly patients and a corresponding number of 
younger ones were analyzed. Preoperative KPS >70 indicated longer overall survival. Statistically sig-
nificant correlation was recorded in both the control (p=0.036) and case (p=0.0053) groups. lower 
postoperative KPS was significantly correlated with shorter OS in elderly patients (p=0.023). The 
correlation between the extent of tumor resection and OS was statistically significant in younger pa-
tients only (p=0.04). Overall survival was significantly shorter in elderly patients regardless of the ex-
tent of tumor resection (p=0.0057). Adjuvant therapy was significantly associated with longer OS in 
both the case (p=0.032) and control (p=0.013) groups. elderly population is a more endangered group 
of surgical brain glioblastoma patients having lower quality of life and shorter overall survival. The 
management protocol should be personalized for each individual case in this age group of patients to 
reduce postoperative complications and grant a satisfactory quality of life.
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Introduction
glioblastoma is the most common primary malig-
nant intracranial tumor with the incidence of 
4-5/100,000 per year1,2. despite advances in molecular 
diagnostics and therapy, overall survival (OS) of glio-
blastoma patients is poor, ranging from 8 to 11 months 
in many studies for most patients3,4. in elderly patients, 
standard treatment (surgery-radiotherapy-chemother-
apy) is not defined yet and there is little agreement 
about the real benefit of specific treatment modalities 
affecting the quality of life5,6.
Surgery is the first step of treatment of glioblasto-
ma in resectable locations in younger patients, but 
many elderly patients have a poor clinical outcome 
without a chance of completing the standard protocol 
of therapy. moreover, the selection of patients who 
may benefit from standard treatment is difficult and no 
validated stratification tools are currently available. 
nevertheless, it appears that elderly patients benefit 
less from surgery regarding survival and quality of life.
for this purpose, the authors analyzed their insti-
tution experience in respect to treatment modalities 
applied, management outcomes and OS in a series of 
brain glioblastoma surgical patients aged over 75 years 
in comparison to younger ones.
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Patients and Methods
we compared clinical and radiological data in 20 
elderly patients (≥75 years) and 20 younger ones (≤65 
years) affected by cerebral glioblastoma and operated 
on at the department of neurosurgery, university of 
Ancona, from January 2012 until January 2015. The 
groups were matched for clinical variables, surgical 
outcomes, adjuvant therapy, Karnofsky Performance 
Scale (KPS) and OS.
All procedures performed in the study were in ac-
cordance with ethical standards of the institutional 
and/or national research committee and the 1964 hel-
sinki declaration and its later amendments or compa-
rable ethical standards. An informed consent was ob-
tained from all participants included in the study.
Surgery was indicated for treatment of space-occu-
pying and/or symptomatic tumor lesions. All patients 
underwent preoperative magnetic resonance imaging 
(mri) study and brain computed tomography (Ct) 
scan, which was repeated 24/48 hours after surgery 
and at 3-6-12-month follow-ups. baseline demo-
graphic and medical data including patient gender and 
age at admission, major presenting symptoms, tumor 
location and grade of resection were evaluated. histo-
pathologic grading according to the world health 
Organization (whO) criteria and molecular markers 
(mgmt and idh1/2) were determined from histo-
pathological reports. Surgical resection was catego-
rized as biopsy, subtotal tumor resection (Str) or total 
tumor macroscopic resection (ttr). Patients with no 
history of epileptic seizures were treated with prophy-
lactic anticonvulsant therapy preoperatively (leveti-
racetam 500 mg twice a day for 2-4 weeks). in case of 
epileptic seizures, therapy was prolonged. to assess the 
quality of life, KPS was evaluated before surgery, 48 
hours after surgery and at 2-month follow-up. radio-
therapy and chemotherapy adjuvant treatment, pro-
gression free survival (PfS) and OS were recorded and 
analyzed.
The PfS was defined as the interval between initial 
surgery and radiological progression of disease. The 
OS was defined as the interval between initial surgery 
and the date of death. The radiotherapy treatment con-
sisted of conventional radiation therapy defined as 50-
60 gy delivered in 20-30 fractions. Chemotherapy 
protocol included temozolomide, which was adminis-
tered at a dose of 75 mg/m2 daily, followed by six cycles 
of 200 mg/m2 for 5 days every 4 weeks. All patients 
were screened for idh1/2 mutations by direct se-
quencing, and for promoter status of mgmt gene by 
the methylation-specific polymerase chain reaction.
All data of elderly patients comprising the case 
group were compared with data from the control group 
of patients aged <65. Kaplan-meyer survival curves 
and univariate logistic regression were used on statisti-
cal analysis. The variables with p<0.05 were considered 
statistically significant. The software used for analysis 
was the SPSS version 19 (ibm, Armonk, new york, 
uSA).
Results
from January 2012 until January 2015, we operat-
ed on 20 patients aged >75 affected by cerebral glio-
blastoma (case group) and 20 patients younger than 65 
(control group). baseline characteristics of the entire 
sample are summarized in table 1. univariate logistic 
regression of preoperative and postoperative variables 
tested for the entire sample are depicted in table 2. 
univariate logistic regression of preoperative and post-
operative variables tested for the case and control 
groups separately are shown in table 3.
in the case group consisting of 20 patients, the im-
provement on KPS 48 hours after surgery was by 10 
points in four patients, 20 points in four patients and 
30 points in one patient, while KPS was unchanged in 
seven patients. The KPS values worsened in four out of 
20 patients. One patient died one week after surgery 
due to cardiovascular failure. At 2-month follow-up, 
systemic complications occurred in three out of 19 pa-
tients and KPS worsened in ten (52.6%) patients.
in the control group, median preoperative KPS was 
65.2, postoperative 72.5, and 70.5 at 2-month follow-
up. no systemic postoperative complications were re-
corded.
in 12 elderly patients having undergone ttr fol-
lowed by oncologic standard treatment, the OS was 
7.8 months versus 6.0 months only in eight patients 
having undergone Str. in the control group, median 
survival was 12.0 months in ttr patients and 5.9 
months in Str patients. no mortality was document-
ed in the control group.
A preoperative KPS >70 was associated with lon-
ger OS in both younger (p=0.036) and elderly (p= 
0.0053) patients, which was statistically significant.
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The correlation between the extent of tumor resec-
tion and OS was statistically significant in the control 
group of younger patients only (p=0.04) (fig. 1Ab). 
The correlation between postoperative KPS and OS 
was statistically significant in the case group of elderly 
patients only (p=0.023) (fig. 2Ab).
Adjuvant therapy was associated with longer OS 
in both groups of patients (table 2). The OS was 
7.0 months in the case group of elderly patients 
and 12.0 months in the control group of younger pa-
tients, yielding a statistically significant difference 
(p=0.0057).












total number  
of patients 20 20
Age (years)
(mean ± Sd) 78 (±3.15) 58.25 (±3.71) /
range 75-85 39-65
Gender
male 8 (40%) 9 (45%)
female 12 (60%) (55%) >0.05
Tumor location
frontal 5 (25%) 7 (35%)
Parietal 7 (35%) 5 (25%)
temporal 5 (25%) 5 (25%)
Occipital 3 (15%) 3 (15%) >0.05
Preoperative KPS
(mean ± Sd) 63 (±8.87) 65.23 (±7.57)
≥70 10 (50%) 9 (45%)
<70 10 (50%) 11 (55%) >0.05
Extent of resection
ttr 12 (60%) 13 (65%)
Str 8 (40%) 7 (35%) >0.05
Adjuvant therapy
rt + Cht 10 (50%) 15 (75%)
rt 2 (10%) 4 (20%)
none 8 (40%) 1 (5%) >0.05
IDH1/2 mutation
yes 0 1 (5%)
no 20 (100%) 19 (95%) >0.05
MGMT promoter
methylated 7 (35%) 12 (60%)
unmethylated 13 (65%) 8 (40%) 0.19
Sd = standard deviation; KPS = Karnofsky Performance Scale; 
ttr = total tumor resection; Str = subtotal tumor resection; rt 
= radiotherapy; Cht = chemotherapy
Table 2. Univariate logistic regression of preoperative 
and postoperative variables in the entire study sample
variable Overall (40 patients)
 OS(months) hr 95% Ci p value
Age (years)     
>75 7    
<65 12    
 / 2.51 1.48 to 10.3 0.0056
Preoperative 
KPS     
≥70 11    
<70 7    
 / 0.39 0.09 to 0.66 0.0052
Extent  
of resection     
ttr 9    
Str 6    
 / 0.47 0.11 to 0.92 0.034
Postoperative 
KPS     
≥70 8.5    
<70 7    
  0.58 0.16 to 1.3 0.14
Adjuvant 
therapy     
rt + Cht 10    
rt 7    
none 3   





0.39 0.09 to 0.66 0.0052
OS = overall survival; hr = hazard ratio; Ci = confidence interval; 
KPS = Karnofsky Performance Scale; ttr = total tumor resection; 
Str = subtotal tumor resection; rt = radiotherapy; Cht = che-
motherapy
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Considering idh1/2 mutations, they were detect-
ed in only one (5%) patient from the control group, 
whereas none of the case group patients presented 
with idh1/2 mutations. due to the almost complete 
absence of idh1/2 mutations in our sample, statistical 
analysis of correlation between these molecular mark-
ers and OS was not possible.
methylation of the mgmt gene promoter was 
found in 12 (60%) patients from the control group and 
seven (35%) patients from the case group. On univari-
ate logistic regression, the OS was significantly longer 
in patients with methylation of the mgmt promoter 
in both groups (p=0.0052) (table 2).
Discussion
glioblastoma (whO grade iv) is the most com-
mon malignant primary brain tumor in adults2,7. Stan-
dard treatment for patients with glioblastoma is surgi-
cal resection with adjuvant therapy (radiotherapy and 
chemotherapy). due to the presence of comorbidities 
in elderly patients, the benefit from standard treatment 
has been questioned5,6,8. Accordingly, many studies 
have shown an increased postoperative mortality and 
morbidity in elderly patients9. however, the treatment 
of glioblastoma in elderly patients has become an ev-
eryday issue due to prolonged life expectation in the 
general population.
in this study, the modality and outcomes of treat-
ment of 20 glioblastoma surgical patients aged >75 
were evaluated and compared to a younger group of 
patients (≤65 years).
As previously reported in the literature, a statisti-
cally significant correlation between preoperative KPS 
and the length of OS was established regardless of pa-
Table 3. Univariate logistic regression of preoperative and postoperative variables in case group (elderly, age >75)  
and control group (younger, age <65)
variable Case group (elderly)(20 patients)  
Control group (younger)
(20 patients)
 OS(months) hr 95% Ci p 
OS
(months) hr 95% Ci p 
Preoperative KPS         
≥70 9    12    
<70 3    7.5    
  0.35 0.059 to 0.77 0.019 / 0.39 0.038 to 0.95 0.043
Extent of resection         
ttr 7.8    12    
Str 6    5.9    
 / 0.77 0.22 to 2.31 0.57  0.27 0.08 to 0.75 0.02
Postoperative KPS         
≥70 8.5    11    
<70 4    8.3    
  0.037 0.05 to 0.81 0.02  0.42 0.02 to 1.53 0.42
Adjuvant therapy         
rt + Cht 10      12   
rt 8      9   
none 2     3  




0.51 0.12 to 0.98 0.0001 0.39 0.18 to 0.85 0.0001
OS = overall survival; hr = hazard ratio; Ci = confidence interval; KPS = Karnofsky Performance Scale; ttr = total tumor resection; Str 
= subtotal tumor resection; rt = radiotherapy; Cht = chemotherapy
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tient age10. in our series, KPS values at 2-month fol-
low-up were lower than the preoperative ones in more 
than half (10/19) of elderly patients. On the contrary, 
KPS values at 2-month follow-up obtained for young-
er patients were higher than the preoperative ones.
data analysis showed that postoperative KPS val-
ues were significantly correlated to OS in the case 
group of elderly patients only (p=0.023), where post-
operative neurological worsening appeared to be criti-
cal. in this group, new deficits were associated with 
poor quality of life and decreased survival. for these 
reasons, standard protocols of adjuvant radiotherapy 
and/or chemotherapy are often denied in such pa-
tients10-14.
in one elderly patient from our series, glioblastoma 
was asymptomatic and it was diagnosed after a poly-
trauma with vertebral fracture treated with screws and 
rods15,16. This patient developed deep vertebral infec-
Fig. 1. Kaplan-Meier overall survival (OS) curves demonstrating significantly improved survival  
in patients having undergone total tumor resection (TTR). Improved survival was only observed in younger 
patients (B, control group) with subtotal tumor resection (STR) in contrast to elderly ones (A, case group).
Fig. 2. Kaplan-Meier overall survival (OS) curves demonstrating significantly improved survival in patients 
with postoperative Karnofsky Performance Scale (KPS) >70 from both groups. Significantly improved survival 
was observed only in elderly patients (A, case group) with postoperative KPS <70 in contrast to the younger ones 
(B, control group).
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tion four months after surgery during radiotherapy 
and chemotherapy treatment, which was cured with 
broad-spectrum antibiotics eliminating the need of 
spinal instrumentation removal17-19.
Several relevant studies demonstrated that ad-
vanced age may be associated with poor prognosis in 
glioblastoma patients3,4,20-22. The same was also ob-
served in our series, where the group of elderly patients 
had significantly shorter OS when compared to the 
younger ones (p=0.0057).
Although some authors stress the importance of 
the extent of resection regardless of age12, we found the 
extent of tumor resection (total or subtotal) to be sig-
nificantly correlated with OS in younger patients only 
(p=0.04), whereas in elderly patients this correlation 
was not statistically significant. Accordingly, it seems 
that the extent of tumor resection is not an essential 
prognostic predictor in elderly patients. Since the 
presence of comorbidities and preservation of good 
clinical status are more relevant for elderly patients, 
the extent of tumor resection seems not to be a deter-
mining factor influencing OS. hence, aggressive sur-
gical treatment in elderly patients to achieve ttr is 
not always proposed, since it bears a high risk of neu-
rological deterioration and/or complications, which in 
turn may preclude adjuvant therapy and early mobili-
zation, leading to poor outcome. Accordingly, our data 
suggested that elderly patients who were able to com-
plete standard treatment protocol (surgery, chemo-
therapy and radiotherapy) showed the best OS. in the 
light of this finding, minimally invasive treatment op-
tions may decrease the post-surgical complication 
rates23, and early rehabilitation may help maintain in-
tact neurological status in elderly patients24.
remembering our results, adjuvant therapy was as-
sociated with longer OS in elderly patients, which is 
consistent with other reports stressing that bimodal 
adjuvant treatment improves survival in the aging25.
nowadays, characterization of molecular biomark-
ers represents an integral part of modern neuro-oncol-
ogy and can help in the management of glioblastoma 
patients too. literature data indicate that idh muta-
tions, which are associated with secondary glioblasto-
ma, are a consistent prognostic marker in low-grade 
and high-grade gliomas26-28. however, due to the al-
most complete absence of idh1/2 mutations in our 
sample, statistical analysis of the correlation between 
these molecular markers and survival was not possible.
Another molecular marker investigated in this 
study was promoter status of the mgmt gene. Our 
study confirmed that OS was significantly longer in 
patients with methylation of the mgmt promoter in 
both groups of patients regardless of their age. Several 
clinical studies have shown that methylation of the 
mgmt promoter is a strong and independent prog-
nostic factor associated with prolonged PfS and 
OS27,29-32. however, this observation was not previ-
ously reported for patients over 75 years of age, which 
may be an original contribution of our study.
in conclusion, remembering the limited number of 
patients in our series, our results suggest that surgery 
can be successfully performed in selected glioblastoma 
patients in spite of their age, in respect to quality of life 
and OS. however, elderly population is a more endan-
gered group of surgical brain glioblastoma patients 
having lower quality of life and shorter OS. Careful 
preoperative stratification, tailored surgical approach 
and balanced adjuvant therapy are beneficial for recov-
ery and prognosis. Therefore, the management proto-
col should be personalized for each individual case in 
this age group of patients to reduce postoperative 
complications and grant a satisfactory quality of life.
References
 1. dolecek tA, Propp Jm, Stroup ne, Kruchko C. CbtruS 
statistical report: Primary brain and central nervous system tu-
mors diagnosed in the united States in 2005-2009. neuro On-
col. 2012;14(Suppl 5):v1-49. doi: 10.1093/neuonc/nos218.
 2. Zhang AS, Ostrom Qt, Kruchko C, rogers l, Peereboom 
dm, barnholtz-Sloan JS. Complete prevalence of malignant 
primary brain tumors registry data in the united States com-
pared with other common cancers, 2010. neuro Oncol. 2017; 
19(5):726-35. doi: 10.1093/neuonc/now252.
 3. Álvarez de eulate-beramendi S, Álvarez-vega mA, balbin m, 
Sanchez-Pitiot A, vallina-Alvarez A, martino-gonzález J. 
Prognostic factors and survival study in high-grade glioma in 
the elderly. br J neurosurg. 2016;30(3):330-6. 
 doi: 10.3109/02688697.2016.1139049.
 4. babu r, Komisarow Jm, Agarwal vJ, rahimpour S, iyer A, 
britt d, et al. glioblastoma in the elderly: the effect of aggres-
sive and modern therapies on survival. J neurosurg. 2016; 
124(4):998-1007. doi: 10.3171/2015.4.JnS142200.
 5. bauman gS, gaspar le, fisher bJ, halperin eC, macdonald 
dr, Cairncross Jg. A prospective study of short-course radio-
therapy in poor prognosis glioblastoma multiforme. int J ra-
diat Oncol biol Phys. 1994;29(4):835-9.
 6. marijnen CA, van den berg Sm, van duinen Sg, voormolen 
Jh, noordijk em. radiotherapy is effective in patients with 
M. Dobran et al. Treatment and outcome of brain glioblastoma in elderly patients
Acta Clin Croat, Vol. 58, No. 2, 2019 227
glioblastoma multiforme with a limited prognosis and in pa-
tients above 70 years of age: a retrospective single institution 
analysis. radiother Oncol. 2005;75(2):210-6. doi: 10.1016/j.
radonc.2005.03.004.
 7. Ostrom Qt, gittleman h, farah P, Ondracek A, Chen y, wo-
linsky y, et al. CbtruS statistical report: Primary brain and 
central nervous system tumors diagnosed in the united States 
in 2006-2010. neuro Oncol. 2013;15(Suppl 2):1-56. doi: 
10.1093/neuonc/not151.
 8. morgan er, norman A, laing K, Seal md. treatment and 
outcomes for glioblastoma in elderly compared with non-el-
derly patients: a population-based study. Curr Oncol. 2017;24 
(2):e92-e98. doi: 10.3747/co.24.3424.
 9. brell m, ibáñez J, Caral l, ferrer e. factors influencing surgi-
cal complications of intra-axial brain tumours. Acta neurochir. 
2000;142(7):739-50.
10. lorimer Cf, hanna C, Saran f, Chalmers A, brock J. Chal-
lenges to treating older glioblastoma patients: the influence of 
clinical and tumour characteristics on survival outcomes. Clin 
Oncol. 2017;S0936-6555(17)30275-3. 
 doi: 10.1016/j.clon.2017.05.010.
11. Kumar n, Kumar P, Angurana Sl, Khosla d, Kumar mukher-
jee K, Aggarwal r, et al. evaluation of outcome and prognostic 
factors in patients with glioblastoma multiforme: a single insti-
tution experience. J neurosci rural Pract. 2013;4(Suppl 1): 
S46-S55. doi: 10.4103/0976-3147.116455.
12. Oszvald A, güresir e, Setzer m, vatter h, Senft C, Seifert v, 
et al. glioblastoma therapy in the elderly and the importance of 
the extent of resection regardless of age. J neurosurg. 2012; 
16(2):357-64. doi: 10.3171/2011.8.JnS102114.
13. Stark Am, van de bergh J, hedderich J, mehdorn hm, naba-
vi A. glioblastoma: clinical characteristics, prognostic factors 
and survival in 492 patients. Clin neurol neurosurg. 2012; 
114(7):840-5. doi: 10.1016/j.clineuro.2012.01.026.
14. tanaka S, meyer fb, buckner JC, uhm Jh, yan eS, Parney if. 
Presentation, management, and outcome of newly diagnosed 
glioblastoma in elderly patients. J neurosurg. 2013;118(4): 
786-98. doi: 10.3171/2012.10.JnS112268.
15. dobran m, iacoangeli m, di Somma lgm, di rienzo A, Co-
lasanti r, nocchi n, et al. neurological outcome in a series of 
58 patients operated for traumatic thoracolumbar spinal cord 
injuries. Surg neurol int. 2014;5(Suppl 7):S329-S332. doi: 
10.4103/2152-7806.139645.
16. dobran m, nasi d, brunozzi d, di Somma lgm, gladi m, 
iacoangeli m, et al. treatment of unstable thoracolumbar junc-
tion burst fractures: short-segment pedicle fixation with inclu-
sion of fracture level versus long-term instrumentation. Acta 
neurochir (wien). 2016;158(10):1883-9. 
 doi: 10.1007/s00701-016-2907-0.
17. dobran m, mancini f, nasi d, Scerrati m. A case of deep in-
fection after instrumentation in dorsal spinal surgery: the man-
agement with antibiotics and negative wound pressure without 
removal of fixation. bmJ Case rep. 2017;pii: bcr-2017-220792. 
doi: 10.1136/bcr-2017-220792.
18. dobran m, marini A, nasi d, gladi m, liverotti v, della 
Costanza m, et al. risk factors of surgical site infections in in-
strumented spine surgery. Surg neurol int. 2017;8:212. doi: 
10.4103/sni.sni 222 17.
19. dobran m, marini A, gladi m, nasi d, Colasanti r, benigni 
r, et al. deep spinal infection in instrumented spinal surgery: 
diagnostic factors and therapy. g Chir. 2017;38(3):124-9. doi: 
10.11138/gchir/2017.38.3.124.
20. Chaichana Kl, Chaichana KK, Olivi A, weingart Jd, bennett 
r, brem h, et al. Surgical outcomes for older patients with 
glioblastoma multiforme: preoperative factors associated with 
decreased survival. Clinical article. J neurosurg. 2011;114(3): 
587-94. doi: 10.3171/2010.8.JnS1081.
21. Kuhnt d, becker A, ganslandt O, bauer m, buchfelder m, 
nimsky C. Correlation of the extent of tumor volume resection 
and patient survival in surgery of glioblastoma multiforme with 
high-field intraoperative mri guidance. neuro Oncol. 2011; 
13(12):1339-48. doi: 10.1093/neuonc/nor133.
22. noorbakhsh A, tang JA, marcus lP, mcCutcheon b, gonda 
dd, Schallhorn CS, et al. gross-total resection outcomes in an 
elderly population with glioblastoma: a Seer-based analysis. J 
neurosurg. 2014;120(1):31-9. doi: 10.3171/2013.9.JnS13877.
23. iacoangeli m, nocchi n, nasi d, di rienzo A, dobran m, 
gladi m, et al. minimally invasive supraorbital key-hole ap-
proach for the treatment of anterior cranial fossa meningiomas. 
neurol med Chir. 2016;56(4):180-5. doi: 10.2176/nmc.
oa.2015-0242.
24. morreale m, marchione P, Pili A, lauta A, Castiglia Sf, Spal-
lone A, et al. early versus delayed rehabilitation treatment in 
hemiplegic patients with ischemic stroke: proprioceptive or 
cognitive approach? eur J Phys rehabil med. 2016;52(1):81-9.
25. Konglund A, helseth r, lund-Johansen m, helseth e, mel-
ing tr. Surgery for high-grade gliomas in the aging. Acta 
neurol Scand. 2013;128(3):185-93. doi: 10.1111/ane.12105.
26. Juratli tA, Kirsch m, robel K, Soucek S, geiger K, von Kum-
mer r, et al. idh mutations as an early and consistent marker 
in low-grade astrocytomas whO grade ii and their consecu-
tive secondary high-grade gliomas. J neurooncol. 2012;108 
(3):403-10. doi: 10.1007/s11060-012-0844-1.
27. Juratli tA, Kirsch m, geiger K, Klink b, leipnitz e, Pinzer t, 
et al. The prognostic value of idh mutations and mgmt pro-
moter status in secondary high-grade gliomas. J neurooncol. 
2012;110(3):325-33. doi: 10.1007/s11060-012-0977-2.
28. nobusawa S, watanabe t, Kleihues P, Ohgaki h. idh1 muta-
tions as molecular signature and predictive factor of secondary 
glioblastomas. Clin Cancer res. 2009;15(19):6002-7. doi: 
10.1158/1078-0432.CCr-09-0715.
29. dunn J,  baborie A, Alam f, Joyce K, moxham m, Sibson r, 
et al. extent of mgmt promoter methylation correlates with 
outcome in glioblastomas given temozolomide and radio-
therapy. br J Cancer. 2009;101(1):124-31. doi: 10.1038/sj.
bjc.6605127.
30. rivera Al, Pelloski Ce, gilbert mr, Colman h, de la Cruz 
C, Sulman eP, et al. mgmt promoter methylation is predic-
M. Dobran et al. Treatment and outcome of brain glioblastoma in elderly patients
228 Acta Clin Croat, Vol. 58, No. 2, 2019
tive of response to radiotherapy and prognostic in the absence 
of adjuvant alkylating chemotherapy for glioblastoma. neuro 
Oncol. 2010;12(2):116-21. 
 doi: 10.1093/neuonc/nop020.
31. brandes AA, franceschi e, tosoni A, blatt v, Pession A, tal-
lini g, et al. mgmt promoter methylation status can predict 
the incidence and outcome of pseudoprogression after con-
comitant radiochemotherapy in newly diagnosed glioblastoma 
patients. J Clin Oncol. 2008;26(13):2192-97. doi: 10.1200/
JCO.2007.14.8163.
32. Stojsavljević m, tasić g, nikolić i, repac n, Janićijević A, 
Sćepanović v, rotim K, rasulić l. glioblastoma multiforme 
brain tumors located in the motor cortex – specific findings in 
comparison with low grade gliomas of the same localization: 
analysis of a sixty patient series. Acta Clin Croat. 2015;54 
(4):402-8.
Sažetak
ZnAČAJKe liJeČenJA i iShOdA u StAriJih bOleSniKA S gliOblAStOmOm mOZgA:  
retrOSPeKtivnA AnAliZA niZA SluČAJevA
M. Dobran, D. Nasi, M. Della Costanza, M. Gladi, M. Iacoangeli, K. Rotim i B. Splavski
modaliteti liječenja od utjecaja na kvalitetu života i preživljavanje starijih bolesnika s glioblastomom još nisu jasno odre-
đeni. Kako bi se utvrdila prognostička razlika u primijenjenim oblicima liječenja u odnosu na dob bolesnika analizirani su 
podaci dobiveni trogodišnjim istraživanjem uzorka. istraživani su sljedeći pokazatelji: Karnofskyjeva ljestvica (KPS), vrijeme 
ukupnog preživljavanja i primjena pomoćnog liječenja. Oglednu skupinu činili su stariji bolesnici (≥75 godina), a kontrolnu 
skupinu oni mlađe dobi (≤65 godina). međusobno su uspoređivani istraživani parametri iz obje skupine bolesnika. Proma-
trano je 20 starijih i odgovarajući broj mlađih bolesnika. Prijeoperacijski KPS >70 upućivao je na dulje sveukupno preživ-
ljavanje. Statistički značajna korelacija zabilježena je u bolesnika kontrolne (p=0,036) i ogledne (p=0,0053) skupine. niže 
poslijeoperacijske vrijednosti KPS bile su značajno povezane s kraćim vremenom preživljavanja u starijih bolesnika (p=0,023). 
Korelacija između opsežnosti tumorske resekcije i sveukupnog preživljavanja bila je statistički značajna samo u mlađoj  dobnoj 
skupini (p=0,04). vrijeme sveukupnog preživljavanja bilo je značajno kraće u starijih bolesnika neovisno o stupnju kirurške 
resekcije (p=0,0057). Primjena pomoćne terapije bila je značajno povezana s duljim sveukupnim preživljavanjem u oglednoj 
(p=0,032) i kontrolnoj (p=0,013) skupini. u zaključku, starija je populacija ugroženija skupina kirurških bolesnika s gliobla-
stomom u kojih je smanjena kvaliteta života i skraćeno vrijeme sveukupnog preživljavanja. Stoga je potrebno protokol liječe-
nja prilagoditi svakom pojedinom bolesniku iz ove dobne skupine kako bi se smanjio udio poslijeoperacijskih komplikacija i 
poboljšala kvaliteta života.
Ključne riječi: Glioblastom; Modaliteti liječenja; Prognoza; Stariji bolesnici; Uspješnost liječenja
